NCT06926192 Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
| NCT ID | NCT06926192 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College |
| Condition | Hidradenitis Suppurativa (HS) |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2020-01-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2020-01-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.
Eligibility Criteria
Inclusion Criteria: 1. Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) HS 2. The diagnosis of HS was confirmed by histopathological examination in the Department of Pathology of our hospital 3. Patients with HS who received secukinumab combined with surgery in the Department of Dermatologic Surgery of our hospital 4. Patients with complete clinical data followed up for at least 1 year Exclusion Criteria: 1. Patients lost to follow-up 2. Patients with less than one year of follow-up 3. Patients who received additional adjuvant therapy during the follow-up period
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06926192 clinical trial?
This trial is open to participants of all sexes, up to 80 Years, studying Hidradenitis Suppurativa (HS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06926192 currently recruiting?
Yes, NCT06926192 is actively recruiting participants. Contact the research team at 19943909917@163.com for enrollment information.
Where is the NCT06926192 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06926192 clinical trial?
NCT06926192 is sponsored by Peking Union Medical College. The trial plans to enroll 100 participants.